Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by CCLA Investment Management

CCLA Investment Management grew its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 20.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 535,050 shares of the life sciences company's stock after purchasing an additional 91,122 shares during the period. CCLA Investment Management owned approximately 0.34% of Illumina worth $71,493,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in shares of Illumina in the 2nd quarter worth $466,000. Envestnet Asset Management Inc. grew its position in shares of Illumina by 1.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 319,834 shares of the life sciences company's stock worth $33,384,000 after buying an additional 3,564 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in Illumina during the second quarter valued at approximately $649,000. Plato Investment Management Ltd lifted its position in Illumina by 30.5% during the second quarter. Plato Investment Management Ltd now owns 4,073 shares of the life sciences company's stock valued at $425,000 after acquiring an additional 953 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new stake in Illumina in the second quarter valued at approximately $44,349,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Down 0.2 %

NASDAQ ILMN traded down $0.29 during trading hours on Wednesday, hitting $136.19. 1,676,777 shares of the company were exchanged, compared to its average volume of 1,780,517. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The firm has a market cap of $21.60 billion, a price-to-earnings ratio of -13.67 and a beta of 1.11. The company has a 50 day moving average of $140.55 and a two-hundred day moving average of $133.10. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the firm earned $0.33 earnings per share. The business's quarterly revenue was down 3.5% compared to the same quarter last year. Equities research analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ILMN. Canaccord Genuity Group raised their price objective on Illumina from $130.00 to $145.00 and gave the stock a "hold" rating in a research report on Tuesday, November 5th. Royal Bank of Canada boosted their target price on shares of Illumina from $252.00 to $254.00 and gave the company an "outperform" rating in a research report on Tuesday, November 5th. Hsbc Global Res upgraded Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Robert W. Baird increased their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 6th. Finally, Piper Sandler reduced their price objective on shares of Illumina from $195.00 to $185.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Illumina currently has an average rating of "Moderate Buy" and an average target price of $165.63.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.